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Abstract
Adverse effects and gastrointestinal toxicity limit the use of Diclofenac, a frequently-used NSAID for treatments of rheumatic disorders
and other chronic inflammatory diseases. Diclofenac-carrier formulations may alleviate adverse effects, increase efficacy and allow local
administration. We report here our first step, biophysical and biochemical investigations of Diclofenac formulated in our previously-developed
bioadhesive liposomes carrying hyaluronan (HA-BAL) or collagen (COL-BAL) on their surface. Both liposome types encapsulated Diclofenac at
high efficiency, encapsulated doses reaching 13mg drug/ml, and performed as sustained-release Diclofenac depots, half-lives of drug release
(under fastest conditions) ranging from 1 to 3days. Therapeutic activity of liposomal Diclofenac was evaluated in CT-26 cells that possess the
CD44 hyaluronan receptors and integrins, and are a bench-mark for intracellular COX enzymes. HA-BAL and COL-BAL showed high cellular-
affinity that was 40 fold and 6 fold over that of regular liposomes. Free, and liposome-encapsulated, Diclofenac showed similar activities. For
example: 2–3nM Diclofenac given to intact cells generated COX-inhibition levels in the range of 60–70% for free drug and for encapsulated drug
in COL-BAL and in HA-BAL. We propose these novel Diclofenac formulations possess key physicochemical and biochemical attributes for task
performance, meriting the next step into in vivo studies.
© 2008 Elsevier B.V. All rights reserved.Keywords: Osteoarthritis; Diclofenac; Cyclooxygenase; Drug carriers; Hyaluronan; Collagen1. Introduction
Age, major trauma, and repetitive joint use, are the main
risk factors in osteoarthritis (OA), the most common form of
joint disease. OA is an organ disease caused by the violation
of balance between synthesis and degradation of cartilage, in
which all tissues are affected — synovial joint, subchondral
bone, synovium, meniscus and cartilage [1,2]. Current available
treatment is of symptoms, directed to relieve the pain and
regain function. For example: oral administration of NSAID
tablets relieves inflammation and pain but causes adverse ef-
fects [3,4]; intra-articular injection of corticosteroids, also re-
lieves inflammation, but cannot be used for chronic treatment
due to adverse effects such as cartilage damage and joint
breakdown [1,2]; intra-articular injection of hyaluronan (HA)
to increase viscoelasiticy of the synovial fluid lessened me-
chanical damage [5,6].⁎ Corresponding author. Tel.: +972 3 640 9822; fax: +972 3 6406834.
E-mail address: rimona@post.tau.ac.il (R. Margalit).
0005-2736/$ - see front matter © 2008 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2008.01.002The NSAID Diclofenac, a reversible inhibitor of both COX1
and COX2, is frequently used in the treatment of OA [2,3,7].
It's oral administration, however, is accompanied by NSAID-
common adverse effects that include gastrointestinal toxicity,
gastric ulcers and anaphylaxis [8,9]. Enteric-coated sustained-
release tablets may alleviate some of these effects, but do not
resolve the problem of gastrointestinal toxicity [10].
Local administration (via intra-articular injection) of Diclo-
fenac formulated in a carrier, may be a viable alternative to oral
administration. It could deliver therapeutic Diclofenac doses to
the target tissue while simultaneously overcoming the drug's
gastrointestinal toxicity and other adverse effects, provided the
carrier possesses the following attributes: an ability to adhere
with high affinity to recognition sites present in the target
area such as extracellular matrix, cartilage, and membrane-
embedded receptors; ability to perform as a site-retained sus-
tained-release Diclofenac depot; composition and structure that
would render the carrier itself biocompatible, biodegradable,
non-toxic and free of adverse effects. Several Diclofenac-carrier
formulations attest to the feasibility of the approach proposed
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Ca2+ designated for oral administration and transfersomes
designated for topical application to intact skin [11,12].
Hypothesizing that our previously-developed bioadhesive
liposomes have the potential to meet the carrier requirements
defined above, we set out to pursue them as Diclofenac car-
riers. To that end, we selected multilamellar liposomes (MLV)
that have hyaluronan (denoted HA-BAL) or collagen (denoted
COL-BAL) anchored covalently to their surface [13–15,18,19].
The rationale driving these selections was based on several
considerations: (i) MLV can provide multiple barriers to drug
diffusion compared to unilamellar liposomes, thus MLV have
higher potential for sustained-release performance and (ii) The
presence of recognition sites at the target zone – such as
hyaluronan receptors (CD44), integrins, extracellular matrix
and cartilage components – to which HA-BAL and COL-BAL
can bind with high affinity [20–25].
We report here the first steps in developing and characteri-
zing Diclofenac-loaded bioadhesive liposomes, focusing on the
molecular and cellular levels of organization. For the latter we
made use of monolayers of intact cells modeling tissues to which
the liposomal Diclofenac will be administered in the future
(by local injection). The molecular studies included studies
on encapsulation efficiency, sustained-release performance and
serum stability. The cellular studies included identification of
CD44 in the cell membrane, cell–liposome binding and, most
notably, therapeutic activity of the liposome-loaded diclofenac
(i.e. COX inhibition).
2. Materials and methods
2.1. Materials
Phospholipon 90G (high purity Soybean phosphatidylcholine (SPC)) was
a kind gift from Nattermann Phospholipid GmbH (Cologne Germany). Di-
palmitoyl phosphatidylethanolamine (DPPE), collagen, Glutaraldehyde, Diclo-
fenac, Arachidonic acid (AA) and Indomethacin were from Sigma Chemical Co.
(St. Louis, USA.) Hyaluronan (HA) was a kind gift from Genzyme, Cambridge
MA. USA). FITC-tagged CD44 antibody (HCAM clone IM7), rat IgG2b was
from Santa Cruz Biotechnology (Santa Cruz, USA). Fetal bovine serum (FBS),
Dulbecco's modified Eagle's medium (DMEM) containing 10% Heat inacti-
vated Fetal Bovine Serum (FBS), 1% Mem-Eagle Non essential amino acids
(X100), 1% L-glutamine, 1% Penicillin (10,000U/ml) + Streptomycin (10mg/ml)
+ Nystatin (1250U/ml) solution, and 0.25% Trypsin – EDTA solution were from
Biological Industries (Beit Haemek, Israel). [14C]Diclofenac, [3H]PGE2 and [
3H]
Cholesterol were from Amersham Pharmacia Biotech (Buckinghamshire, UK).
Costar tissue culture flasks and plates were from Corning (Corning, USA).
Dialysis tubing (molecular weight cutoff of 12,000–14,000) was from Spectrum
Medical Industries (Los Angeles, USA).
Ultracentrifugation was performed with a Sorval Discovery M120 SE micro
ultracentrifuge (Tennessee, USA). Lyophilization was performed with a HETO
Drywinner 3 (Alleraod, Denmark). Fluorescence emission was measured using
a FL 500 microplate fluorescence reader BioTek instruments (Vermont, USA).
2.2. Methods
2.2.1. Regular and bioadhesive drug-free liposomes
Regular MLV (denoted RL) were composed of SPC and DPPE, at the mole
ratio of SPC:DPPE 95:5 and the total lipid concentration of 100mg lipid/ml.
The liposomes were prepared by the “novel” method [16,18], essentially as
previously described except: ethanol replaced chloroform:methanol mixtures
for lipid dissolution, the swelling solution was 0.1M borate buffer at pH 9, andincubation of the dry lipid film was for 2h at 65°C, in a shaker bath. A portion
of these RL was set aside as a control and the remainder was taken to surface
modification, binding hyaluronan or collagen, according to the previously-
reported processes [13–15,19,21,26]. Briefly: to obtain HA-BAL, HAwas dis-
solved in acetate buffer (0.1M, pH 4.5) at the concentration of 2mg/ml, was
preactivated by incubation with EDC (ethyl-dimethyl-aminopropyl-carbodii-
mide) [15–17] for 2h at 37°C. The preactivated HA was mixed with the RL
suspension, at the ratio of 1:1 (v/v).
To obtain COL-BAL, collagen was dissolved in 0.01% acetic acid to the
final concentration of 2mg/ml, allowing 24h at 4°C for complete dissolution.
The collagen was mixed with the RL suspension at a ratio of 1:1 (v/v), followed
by the addition of Glutaraldehyde to a final concentration of 1%.
Each reaction mixture was incubated for 24h under shaking or stirring, at
37°C and 4°C, for the HA-BAL and for COL-BAL, respectively. The bio-
adhesive liposomes were freed from excess materials and by-products by
ultracentrifugation for 30min at 4°C and a g force of 160,850, followed by several
successive washes and re-centrifugations in PBS pH = 7.6, suspending the final
pellets in this buffer. The control RL, were subjected to the same centrifugation
and washing processes. Aliquots of 1ml of the three liposome types – RL, HA-
BAL and COL-BAL – were frozen for 2h at − 80°C, followed by lyophilization.
The resultant liposome powders were stored at − 18°C until further use.
2.2.2. Drug encapsulation and release
Drug encapsulation was performed as follows: The lyophilized liposomes,
brought to room temperature, were re-hydrated with an aqueous solution of
Diclofenac, incubating the systems for 2h at 37°C.
Kinetics of drug release were studied according to our previously-developed
experimental set up and data processing [27–29]. Briefly: a suspension of Dic-
lofenac-encapsulating liposomes was placed in a dialysis sac that was immersed in
a continuously-stirred receiver vessel containing drug-free buffer (PBS pH 7.6),
receiver to liposomes volume ratios was 15. At designated time points, the dialysis
sac was transferred from one receiver vessel to another containing fresh drug-free
buffer. Drug concentration was determined in each dialysate and in the sac (at the
beginning and end of the run). The data were analyzed according to a previously
derived multi-pool kinetics model, expressed in Eq. 1 [14,19,13,19, 27–29]:





where f(t) is the fraction of drug that diffused from the sac to the reservoir at
time = t, normalized to the total drug in the system at time = 0; n is the number
of independent drug pools in the system, fj is the fraction of the total drug in the
system occupying the jth pool at t = 0 and kj is the rate constant for drug diffusion
from the jth pool. These kinetic experiments can also yield the encapsulation
efficiency, which is defined as the ratio of liposome-encapsulated drug to the total
drug in the system: When the kinetic study is performed on the complete system
(i.e. encapsulated and un-encapsulated drug), the value of fj for the encapsulated
pool is also the encapsulation efficiency. The dialysis approach was also used for
the serum stability studies, except the liposome sample in the dialysis sac was
suspended in 1:1 (v/v) PBS:Fetal bovine serum (FBS) and the dialysis was either
against a similar mixture of PBSFBS or against PBS alone. In all studies
diclofenac was assayed using a trace of radioisotope [14C] Diclofenac.
2.2.3. Cell culture growth and maintenance
Monolayers of CT-26 cells (mouse colon carcinoma), PANC-1 cells (human
pancreatic adenocarcinoma), HT-29 cells (human colon cancer) and COS-7 cells
(African green monkey, kidney) were grown in T75 flasks in Dulbecco's modified
Eagle's medium (DMEM) containing 10% Heat inactivated Fetal Bovine Serum
(FBS), 1% Mem-Eagle Non essential amino acids (X100), 1% L-glutamine, 1%
Penicillin (10,000U/ml) + Streptomycin (10mg/ml) +Nystatin (1250U/ml) solution.
Cultures were maintained at 37°C in 5% CO2. For all experiments cells were
harvested from subconfluent cultures using 0.25% Trypsin – EDTA solution and
were resuspended in fresh full serum-supplemented growth medium before plating.
2.2.4. Liposomes binding to cell monolayers
2.2.4.1. CD44 expression. To verify that the CT-26 cells express and harbour
CD44 receptors in their cell membrane, CT-26 cells were plated in a 24-well
plate and the experiment was initiated upon confluency. The cells were
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106 cells. Similar monolayers of COS-7, HT-29 and of PANC-1 cells were used
as negative and positive controls. At the end of the incubation the medium above
the cells was aspirated, the cells were subjected to extensive washing by PBS,
and the fluorescence was determined in a fluorescence plate reader, with
excitation and emission at 485nm and 530nm, respectively.
2.2.4.2. liposome-cell binding. The experiments were carried out as
previously described [14,15,20]. Briefly, 48–72h prior to the experiment CT-
26 cells were seeded onto 24-multiwell plates and the experiment was initiated
upon confluency. The cell-growth media was replaced with 500µl of serum-free
medium containing the desired liposomes at increasing concentrations. In-
cubations were for 60min at 37°C. Upon termination, the medium from each
well was aspirated, and each well was washed three times with PBS. The cells in
each well were lysed with 1N NaOH over night at 37°C. The content of each
well was collected and assayed for total cell protein and for cell-associated
liposomes. Protein assay was by the Bradford method. Liposome assay was by
inclusion of trace [3H]Cholesterol in the formulation which is stable in these
liposomes [14,15,20] applying radioactive counting. Wells receiving free me-
dium alone served as controls. The results were analyzed according to the
Langmuir isotherm [13,15,18,20].
2.2.5. COX inhibition by free and by liposome-encapsulated Diclofenac in
intact cells
CT-26 cells were seeded as described above for binding, except the experiment
was initiated at 70% confluency. The cell-growth media was replaced with 500µl
serum-free media containing a desired Diclofenac formulation (free or liposomal),
ranging from0.1–10nMDiclofenac.Wells receiving drug-freemedium or “empty”
(i.e. drug-free) liposomes served as controls. Incubations were for 30min at 37°C,
followed by addition of the substrate arachidonic acid (AA) at a final concentration
of 30mM. The reaction was arrested after an additional incubation of 20min at
37°C, by the addition of Indomethacin at a final concentration of 5μM. The
medium of each well was collected and subjected to a radioimmunoassay (RIA)
[30] using trace [3H]PGE2 to determine the PGE2 concentration. Determination of
total cell protein was as described in section 4 above.
3. Results and discussion
3.1. Molecular properties of Diclofenac-liposome formulations
Diclofenac encapsulation efficiency was explored as func-
tion of liposome type, liposome concentration and drug con-Fig. 1. Diclofenac (SD) encapsulation efficiency and Diclofenac drug loading, in regu
hand panel: regular liposomes (RL), middle panel: Bioadhesive liposomes with co
liposomes with hyaluronan as the bioadhesive ligand (HA-BAL). In each panel the ba
3 determinations (using the kinetic method) and the error bars represent the stand
(i.e. concentration of encapsulated drug). Liposome concentrations were constant at 1
at the mole ratio of 95:5.centration. At the liposome concentration corresponding to
20mg lipid/ml, Diclofenac encapsulation efficiencies were 40–
50%, even at the low end of drug concentrations (0.1–5mg/ml)
(Data not shown). Increasing the liposome concentration to
100mg lipid/ml generated an increase in encapsulation efficien-
cies as expected from prior studies [29], for all liposome types
tested (Fig. 1). Clearly, it is possible to encapsulate Diclofenac in
liposomes, at high efficiency and – irrespective of drug dose
level – rendering the liposomes bioadhesive does not impair
drug encapsulation (Fig. 1). At low drug doses, encapsulation
efficiency is relatively high and close to complete. With the
increase in drug concentration there is some drop in encapsula-
tion efficiency, yet even close to the limit of drug solubility
(20mg Diclofenac/ml) satisfactory encapsulation efficiencies
of≥ 50% are obtained. Moreover, the tendency of encapsulation
efficiency to decrease at the high end of initial drug concentra-
tions, had no adverse effect on drug loading. The latter increases
continuously with the increase in initial concentration, as also
shown in Fig. 1.
Unidirectional Diclofenac efflux from liposomal formula-
tions showed a multi-phase pattern which was similar in all
three liposome types (Fig. 2A). This pattern is quite similar to
our previous findings for other small molecular weight drugs
corresponding to a two-pool model, one assigned to the un-
encapsulated drug present in the system at time = 0 and the other
to the liposome-encapsulated drug. Data from experiments of
the type shown in Fig. 2, analyzed according to Eq. (1) above,
fit the case of n = 2, as expressed in Eq. (2) below:
f tð Þ ¼ f1 1 expk1t
 þ f2 1 expk2t
  ð2Þ
The magnitudes obtained for k2, the parameter indicative of
the sustained-release nature of the systems, are shown in Fig. 3.
As in the case of encapsulation, and as indicated from the raw
data of Fig. 2, rendering the liposomes bioadhesive did not
affect drug release— neither blocking it, nor accelerating it. Aslar and in bioadhesive liposomes, as function of initial drug concentration. Left-
llagen as the bioadhesive ligand (COL-BAL), right-hand panel: Bioadhesive
rs (left-hand ordinate) represent the encapsulation efficiency, each an average of
ard deviations, and the lines (right-hand ordinate) represent the drug loading
00 mg lipid/ml, and the lipid composition for all liposome types was SPC:DPPE
Fig. 3. The relationship between k2 – the efflux rate constant of liposome-
encapsulated Diclofenac (SD) – and the initial drug concentration, for regular
and for bioadhesive liposomes. Liposome details are similar to those listed in
the legend to Fig. 1. Light-shaded bars: regular liposomes, dark-shaded bars:
hyaluronan bioadhesive liposomes (HA-BAL), diagonal-patterned bars: col-
lagen bioadhesive liposomes (COL-BAL). Each bar is an average of 3 deter-
minations and the error bars represent the standard deviations.
Fig. 2. Kinetics of Diclofenac (SD) efflux from regular and from bioadhesive liposomes, in buffer and in buffer:serum media. Liposome details as those listed in
the legend to Fig. 1. Points are experimental, and the solid curves are the theoretical expectations, drawn according to Eq. (2) in the text. A. Efflux into buffer media.
RL: open squares, HA-BAL: open circles, COL-BAL: open inverted triangles. B. Efflux into buffer or serum media. HA-BAL suspended in PBS and dialyzed against
PBS — open diamonds, HA-BAL suspended in PBS:serum 1:1 and dialyzed against PBS:serum 1:1 — open triangles.
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Diclofenac was found to increases with the increase in initial
drug concentration. Given that such efflux is a multi-step pro-
cess with a single rate-limiting step [14,19,27–29], this increase
implies a reduction in energetic costs either at the same rate-
limiting step or a shift in the location of that step. Yet we wish
to stress that for the entire span of systems, k2 remained within
the range of 0.01–0.03h− 1 corresponding to half-life of drug
release in the range of 1–3days. This is clear support for the
sustained-release nature of these liposomal Diclofenac formu-
lations. The unidirectional flux conditions under which these
experiments were conducted, represent the fastest drug release
expected due to the significant dilution that generates a mas-
sive driving force for diffusion. Such conditions would be
expected to reign when liposomes are administered systemi-
cally. The smaller the dilution of an administered liposome
formulation, the smaller the driving force for drug diffusion,
hence the slower the net efflux. A case of lesser dilution is local,
rather than systemic, administration of drug carrier systems.
Based on these physicochemical considerations, we expect that
designated local administration of diclofenac–liposome for-
mulations, where dilution is significantly less than in the case
of systemic administration, will extend the time span for drug
delivery from each dose well beyond that of 1–3days.
Proteins that are part of the biological environment into
which the liposomal formulations will be administered, may
pose a risk of destabilizing the formulations, which is liposome-
specific rather than drug-specific. To assess this risk at the
molecular level, the kinetic experiments described above were
repeated, suspending the liposomes within the dialysis sac in a
media modeling the protein contents of biological fluids, made
of serum:buffer 1:1 (v/v). Were the liposomes significantly
destabilized, this would have appeared as a significant increase
in the rate of drug release due to liposomal depletion. The
results shown in Fig. 2B are clear indication that this was not the
case, as rates of drug efflux in the presence and absence of
serum are quite similar. Further support for stability of the
bioadhesive liposomes in biological media is drawn fromprevious in vivo studies of antibiotic-encapsulating COL-BAL
[29].
3.2. Cellular properties of Diclofenac–liposome formulations
The hyaluronan-specific receptor family CD44 is known to
be over-expressed in many types of tumors while it is usually
poorly-expressed in normal cells [21,23,26]. In the test cell line
used here, CT-26, CD44 expression is anticipated to correlate
with favored binding of HA-BAL compared to the other types
of liposomes used in this study (i.e., RL and COL-BAL). Such
favored binding may, furthermore, affect COX inhibition by the
liposomal Diclofenac.
The expression of CD44 in the tested CT-26 cells was veri-
fied, as shown in Fig. 4, by the binding of anti CD44 antibody to
these cells as well as to positive controls (i.e., the PANC-1 and the
HT-29) and by the lack of binding to cells devoid of this receptor
family (i.e., the COS-7 cells).
Fig. 5. COX inhibition, expressed as residual COX activity, by free and by
liposome-encapsulated Diclofenac (SD), in intact CT-26 cells. Each set of bars
represents, for each formulation, the increase in enzyme inhibition as function of
increasing drug concentrations. Drug concentrations increase from left to right, as
represented by the gradual increase in the bar-shade density, and the specific values
are listed on the figure. Liposome details are as listed under Fig. 1. Enzyme activity
was determined using arachidonic acid as the substrate, following the increase in
the PGE2 product. Each bar is an average of 6 determinations and the standard
deviations were b10%.
Fig. 4. Binding of FITC-tagged anti CD44 antibody (HCAM clone IM7, rat
IgG2b) to cell monolayers. Each bar is an average of four determinations and the
error bars represent the standard deviations.
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were found to bind to monolayers of CT-26 cells, with a sa-
turating pattern (albeit with quantitative differences among
the liposome types). Data analysis fit a one-term Langmuir
Isotherm [13,15,18,20], and the resultant binding parameters
are listed in Table 1. The interaction of regular liposomes (RL)
with the CT-26 cells is, as expected, non-specific and relative-
ly weak. As anticipated from the presence of CD44 receptors,
HA-BAL bound to the CT-26 cells with high affinity, that was
40 fold higher than that of the RL, with a concomitant drop in
the capacity. The latter is expected, given that the number of
specific sites a cell offers a ligand (i.e. receptors) is usually
smaller than the number of sites for non-specific adsorption.
Binding of these HA-BAL to COS-7 cells (the negative control
cell line lacking CD44 receptors), was of considerable lower
affinity, yielding a Kd of 1.4 mM lipid and a Bmax of 1.2 nmol
lipid/105 cells. These correspond to a 64 fold lower affinity than
to the test CT-26 cells, with a concomitant 11 fold higher Bmax.
Both these parameters, lower affinity and higher capacity are
indicative of non-specific binding. The binding of COL-BAL to
these cells falls in-between those of the RL and the HA-BAL,
showing an affinity which is 6 fold higher than that of RL with a
drop in capacity less-pronounced than in the case of HA-BAL.
These data indicate presence of components on the surface of
the CT-26 cells that are capable of binding collagen (hence
COL-BAL) such as integrins and ECM, but with a lower
specificity than HA-BAL. Nevertheless, both types of bioadhe-
sive liposomes show sufficient binding to perform as site-
retained Diclofenac depots.Table 1
Binding of regular and of bioadhesive multilamellar liposomes to monolayers of
the CT-26 cell line





RL None 3.9 (±0.7) 0.23 (±0.02)
COL-BAL Collagen 0.62 (±0.06) 0.15 (±0.01)
HA-BAL Hyaluronan 0.11 (±0.02) 0.022 (±0.001)Even when, as in the present case, drug encapsulation with-
in a carrier and drug efflux from the carrier are both highly
satisfactory, questions still remain with respect to the desired
biological activity. The processes of encapsulation within a
carrier may damage a drug and cause loss of its activity. In
addition, drug release from the carrier to the cell may be too slow
and too low to provide intracellular activity within a relevant
time frame. The in vitro studies we conducted (Fig. 5) to eva-
luate COX inhibition in intact cells, were designed to address
these questions. Free SD, tested to verify proper response of all
assay components, generated the expected clear dose-dependant
inhibition of COX activity in the intact CT-26 cells (Fig. 5, left-
hand bar set). All three liposomal SD formulations (Fig. 5, right-
hand bar sets) were also clearly active in COX inhibition, on
a par with that of the free drug. These results indicate that
formulation within the liposomes did not damage drug activity
and that the encapsulated drug gained access into the cells. It
may be, moreover, that within the time span of the experiment
only part of the encapsulated drug moved from the liposomes
into the cells. The potency of liposomal SD may, therefore,
be higher than that of free drug. Whether the higher affinity of
HA-BAL to cells expressing the CD44 receptor translates into
a therapeutic advantage for SD formulated in these liposomes
awaits studies in animal models.
4. Conclusions
It follows, from the data presented and discussed, that HA-
BAL and COL-BAL provide high efficiency encapsulation of
SD at therapeutically-relevant doses, can act as sustained-re-
lease depots with half-lives of drug release in the range of 1–
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not the regular, liposomes bind with high affinity to the CT-26
cell line that models target cells in two respects: having the
CD44 receptors for hyaluronan and integrins for collagen;
containing intracellular COX which is the site of Diclofenac
action. The liposome-encapsulated Diclofenac, moreover, re-
mains active and functional as a COX inhibitor. There also
seems to be a correlation, which needs further future cor-
roboration, that the higher the liposomal affinity to the target
cell, CT-26 in the present case, the better it can function as a
site-adherent drug depot.
Taken together, we offer the conclusion that these systems
merit further studies in animal models. Such investigations,
applying local injections of these novel formulations in a rat
model of osteoarthritis, are underway.
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